dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Amer, Fatma |
dc.contributor.author | Yousif, Monkez M |
dc.contributor.author | Hammad, Noha M |
dc.contributor.author | Garcia Cehic, Damir |
dc.contributor.author | Nieto Aponte, Leonardo |
dc.contributor.author | Rodríguez Frias, Francisco |
dc.contributor.author | Quer Sivila, Josep |
dc.contributor.author | Rando Segura, Ariadna |
dc.contributor.author | Gregori Font, Josep |
dc.contributor.author | Esteban Mur, Juan Ignacio |
dc.date.accessioned | 2020-07-29T09:52:30Z |
dc.date.available | 2020-07-29T09:52:30Z |
dc.date.issued | 2019-09-10 |
dc.identifier.citation | Amer F, Yousif MM, Hammad NM, Garcia-Cehic D, Gregori J, Rando-Segura A, et al. Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment. Infect Drug Resist. 2019 Sep 10;12:2799–807. |
dc.identifier.issn | 1178-6973 |
dc.identifier.uri | https://hdl.handle.net/11351/5118 |
dc.description | Resistance-associated substitutions; RAS; Subtype 4a |
dc.description.abstract | Purpose: To study resistance-associated substitutions using next-generation sequencing in Egyptian hepatitis C virus-infected patients failing direct-acting antiviral treatment. Methods: The current study describes three cases of treatment failure in patients referred to Zagazig Viral Hepatitis Treatment Center (ZVHTC), Sharkia Governorate, Egypt. RAS were identified and characterized using deep sequencing. The first patient had breakthrough while receiving a daclatasvir (DCV)+sofosbuvir (SOF) regimen, patient 2 relapsed after treatment with DCV+SOF+ribavirin (RBV), and patient 3 relapsed after DCV+SOF therapy. A serum sample was collected from each patient at failure and sent to Vall d’Hebron Research Institute at Hospital Universitari Vall d’Hebron in Barcelona (Spain) for deep-sequencing study to identify and characterize the RAS present in the samples. Results: The following were identified: L28M, L30S and L28M+L30S in patient 1, L30R in patient 2, and R155C, D168E, L28M, L30H, L30S, L28M+L30H, and L28M+L30S in patient 3. Conclusion: To the best of our knowledge, this is the first report from Egypt of patients failing DAA-based therapy, describing the associated RAS. This information will be of help to understand the natural history of HCV in Egyptian patients and guide the proper choice of retreatment protocols. |
dc.language.iso | eng |
dc.publisher | Dovepress |
dc.relation.ispartofseries | Infection and Drug Resistance;12 |
dc.rights | Attribution-NonCommercial 3.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/ |
dc.source | Scientia |
dc.subject | Hepatitis C - Tractament |
dc.subject | Àcids nucleics - Anàlisi |
dc.subject | Resistència als medicaments |
dc.subject.mesh | Hepatitis C, Chronic |
dc.subject.mesh | Sequence Analysis, RNA |
dc.subject.mesh | Drug Resistance, Multiple, Viral |
dc.subject.mesh | /drug therapy |
dc.title | Deep-sequencing study of HCV G4a resistance-associated substitutions in Egyptian patients failing DAA treatment |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.2147/IDR.S214735 |
dc.subject.decs | hepatitis C crónica |
dc.subject.decs | análisis de secuencias de ARN |
dc.subject.decs | farmacorresistencia viral múltiple |
dc.subject.decs | /tratamiento farmacológico |
dc.relation.publishversion | https://www.dovepress.com/deep-sequencing-study-of-hcv-g4a-resistance-associated-substitutions-i-peer-reviewed-article-IDR |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.authoraffiliation | [Amer F, Hammad NM] Department of Medical Microbiology and Immunology, Faculty of Medicine, Medical College, Zagazig University, Zagazig, Egypt. [Yousif MM] Internal Medicine Department , Faculty of Medicine, Medical College, Zagazig University, Zagazig, Egypt. [Garcia-Cehic D, Esteban JI, Quer J] Unitat d’Hepatologia, Servei de Medicina Interna, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Laboratori sobre els virus de la Hepatitis, Grup de Recerca Malalties Hepàtiques, Vall d'Hebron Institut Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas (CIBERehd) del Instituto de Salud Carlos III, Madrid, Spain. [Gregori J] Unitat d’Hepatologia, Servei de Medicina Interna, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Laboratori sobre els virus de la Hepatitis, Grup de Recerca Malalties Hepàtiques, Vall d'Hebron Institut Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas (CIBERehd) del Instituto de Salud Carlos III, Madrid, Spain. Business Development Department, Roche Diagnostics SL, Sant Cugat del Vallès, Spain. [Rando-Segura A, Nieto-Aponte L] Unitat d’Hepatologia, Servei de Bioquímica i Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Rodriguez-Frias F] Centro de Investigación Biomédica en Red (CIBER) de Enfermedades Hepáticas y Digestivas (CIBERehd) del Instituto de Salud Carlos III, Madrid, Spain. Unitat d’Hepatologia, Servei de Bioquímica i Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 31571936 |
dc.identifier.wos | 000485894000001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI15%2F00856 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F00337 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |